Abstract
Our objective was to examine the association between myocardial infarction (MI) and two DNA-polymorphisms at the proinflammatory chemokine receptors CCR2 (I64V) and CCR5 (32 bp deletion, Δccr5), defining if these polymorphisms influence the age for the onset of MI. A total of 214 patients with an age at the first MI episode <55 years, 96 patients that suffered the first MI episode when older than 60 years, and 360 population controls were polymerase chain reaction genotyped for the CCR2-V64I and CCR5-Δ32/wt polymorphisms. Patients and controls were male from the same Caucasian population (Asturias, northern Spain). The frequency of the Δccr5 allele was significantly higher in controls compared to patients <55 years (P = 0.004), or in patients >60 years compared to patients <55 years (P = 0.002). Taking the patients >60 years as the reference group, non-carriers of the Δccr5-allele would have a three-fold higher risk of suffering an episode of MI at <55 years of age (OR = 3.06; 95% CI = 1.46–6.42). Gene and genotype frequencies for the CCR2 polymorphism did not differ between patients <55 years and controls or patients >60 years. Our data suggest that the variation at the CCR5 gene could modulate the age at the onset of MI. Patients carrying the Δccr5-allele would be protected against an early episode of MI. CCR5 and the CCR5-ligands are expressed by cells in the arteriosclerotic plaque. Thus, the protective role of Δccr5 could be a consequence of an attenuated inflammatory response, that would determine a slower progression of the arteriosclerotic lesion among Δccr5-carriers. Our work suggests that the pharmacological blockade of CCR5 could be a valuable therapy in the treatment of MI.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 digital issues and online access to articles
$119.00 per year
only $19.83 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Libby P Molecular bases of the acute coronary syndromes Circulation 1995 91 2844–2850
Ross R Atherosclerosis: an inflammatory disease N Engl J Med 1999 340 115–126
Baggiolini M, Dewald B, Moser B Interleukin-8 and related chemotactic cytokines: CXC and CC chemokines Adv Immunol 1994 55 97–179
Luster AD Chemokines: chemotactic cytokines that mediate inflammation N Engl J Med 1998 338 436–445
Nelken NA, Coughlin SR, Gordon D, Wilcox JN Monocyte chemoattractant protein-1 in human atheromatous plaques J Clin Invest 1991 88 1121–1127
Ylä-Herttuala S, Lipton BA, Sarkioja ME et al Expression of monocyte chemotactic protein-1 in macrophage rich areas of human and rabbit atherosclerotic lesions Proc Natl Acad Sci USA 1991 88 5252–5256
Damas JK, Gullestad L, Ueland T et al CXC-chemokines, a new group of cytokines in congestive heart failure – possible role of platelets and monocytes Cardiovasc Res 2000 45 428–436
Reape TJ, Groot PH Chemokines and atherosclerosis Atherosclerosis 1999 147 213–225
Weber KS, Nelson PJ, Grone HJ, Weber C Expression of CCR2 by endothelial cells: implications for MCP-1 mediated wound injury repair and in vivo inflammatory activation of endothelium Arterioscl Thromb Vasc Biol 1999 19 2085–2093
Rollins BJ, Yoshimura T, Leonard EJ, Pober JS Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE Am J Pathol 1990 136 1229–1233
Yu X, Dluz S, Graves DT et al Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolaemic primates Proc Natl Acad Sci USA 1992 89 6953–6957
Nelken NA, Coughlin SR, Gordon D, Wicox JN Monocyte chemoattractant protein 1 in human atheromatous plaques J Clin Invest 1991 88 1121–1127
Mantovani A The chemokine system: redundancy for robust outputs Immunol Today 1999 20 254–257
Hayes IM, Jorda NJ, Towers S et al Human vascular smooth cells express receptors for CC chemokines Arterioscler Thromb Vasc Biol 1998 18 397–403
Schecter AD, Calderon TM, Berman AB et al Human vascular smooth muscle cells possess functional CCR5 J Biol Chem 2000 275 5466–5471
Boring L, Gosling J, Cleary M, Charo IF Decreased lesion formation in CCR−/− mice reveals a role for chemokines in the initiation of atherosclerosis Nature 1998 394 894–897
Berger EA HIV entry and tropism: the chemokine receptor connection Aids 1997 11 (Suppl A) S3–S16
Dean M, Carrington M, Winckler C et al Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene Science 1996 273 1856–1862
Lui R, Paxton WA, Choe S et al Homozygous defect in HIV-1 infection Cell 1996 86 367–377
Samson M, Libert F, Doranz BJ et al Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR5 chemokine receptor gene Nature 1996 382 722–725
Huang Y, Paxton WA, Wolinsky SM et al The role of a mutant CCR5 allele in HIV-1 transmission and disease progression Nat Med 1996 2 1240–1243
Kostrikis LG, Huang Y, Moore JP et al A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation Nat Med 1998 4 350–354
Mummidi S, Ahuja SA, González E et al Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression Nat Med 1998 4 786–793
Benkirane M, Jin DY, Chun RF, Koup RA, Jeang KT Mechanism of transdominant inhibition of CCR5 mediated HIV-infection by ccr5Δ32 J Biol Chem 1997 272 30603–30606
Matsumori A, Furukawa Y, Hashimoto T et al Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction J Mol Cell Cardiol 1997 29 419–423
Kuziel WA, Morgan SJ, Dawson TC et al Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in the CC chemokine receptor 2 Proc Natl Acad Sci USA 1997 94 12053–12058
Kurihara T, Warr G, Loy J, Bravo R Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor J Exp Med 1997 186 1757–1762
Alvarez V, López-Larrea C, Coto E Mutational analysis of the CCR5 and CXCR4 genes (HIV-1 co-receptors) in resistance to HIV-1 infection and AIDS development among intravenous drug users Hum Genet 1998 192 483–486
Hall IP, Wheatley A, Christie G et al Association of CCR5 Δ32 with reduced risk of asthma Lancet 1999 354 1264–1265
Garred P, Madsen HO, Petersen J et al CC chemokine receptor 5 polymorphism in rheumatoid arthritis J Rheumatol 1998 25 1462–1465
Cooke SP, Forrest G, Venables PJ et al The delta32 deletion of CCR5 receptor in rheumatoid arthritis Arthritis Rheum 1998 41 1135
Zapico I, Coto E, Rodríguez A et al CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis Genes Immun 2000 1 288–289
Francis SE, Camp NJ, Dewberry RM et al Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease Circulation 1999 99 861–866
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by a grant from the Spanish Health System (Fondo de Investigaciones Sanitarias 99/0924).
Rights and permissions
About this article
Cite this article
González, P., Alvarez, R., Batalla, A. et al. Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction . Genes Immun 2, 191–195 (2001). https://doi.org/10.1038/sj.gene.6363760
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gene.6363760
Keywords
This article is cited by
-
The neurorepellent, Slit2, prevents macrophage lipid loading by inhibiting CD36-dependent binding and internalization of oxidized low-density lipoprotein
Scientific Reports (2021)
-
Prevention of CaCl2-induced aortic inflammation and subsequent aneurysm formation by the CCL3–CCR5 axis
Nature Communications (2020)
-
Emerging role of chemokine CC motif ligand 4 related mechanisms in diabetes mellitus and cardiovascular disease: friends or foes?
Cardiovascular Diabetology (2016)
-
Maraviroc Intensification Improves Endothelial Function in Abacavir-Treated Patients, an Open-Label Randomized Cross-Over Pilot Study
Infectious Diseases and Therapy (2016)
-
CC chemokine ligands in patients presenting with stable chest pain: association with atherosclerosis and future cardiovascular events
Netherlands Heart Journal (2016)